Sangamo and Astellas Announce Capsid License Agreement to Deliver Genomic Medicine for Neurological Diseases

Click here to view

ASGCT 2021

Selective Repression of C9ORF72 Repeat Expansion-Containing Sense and Antisense Transcripts for the Treatment of ALS
June 3rd, 2021
Zinc Finger Protein Transcription Factors Targeting Alpha-synuclein – A Promising Therapeutic Strategy for Parkinson’s Disease
June 1st, 2021